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Abstract
Post-transplant lymphoproliferative disease (PTLD) is a well-known post-transplant malignancy common in both solid
organ and stem cell transplants. The incidence of PTLD in adult liver transplant recipients is approximately 2.8%. While
most often presenting in the first year after transplant, PTLD can occur at any time. This case report narrates a 61-year-old
female with a history of liver transplant in 1992 for autoimmune hepatitis that was found to have a jejunal perforation due
to PTLD 27 years later. The patient presented to the hospital with a fifteen hour history of left sided abdominal pain that
was progressively worsening. The patient reports taking Imuran, Cellcept and Prednisone daily for immunosuppression.
Computed tomography revealed pneumoperitoneum and free fluid centered on a focal area of enteritis in the proximal
jejunum, as well as wall thinning of several areas of the small intestine. The patient was taken to the operating room for
an exploratory laparotomy where a perforation was identified on the antimesenteric portion of the distal jejunum. A
small bowel resection was performed and the patient’s postoperative course was unremarkable. On pathologic analysis
the patient was found to have a monomorphic, diffuse large B-cell lymphoma with a high proliferative rate. This case
demonstrates a rare presentation of post-transplant lymphoproliferative disease occurring 27 years after transplantation.
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Introduction
Post-transplant lymphoproliferative disorder (PTLD) is a
rare but serious group of heterogeneous lymphoproliferative
disorders that may develop after hematopoietic stem cell and
solid organ transplants [1]. It is the second most common
malignancy in transplant patients, the most common being
skin cancer [2]. It is estimated that up to 70-80% of cases
are associated with the Epstein Barr Virus (EBV) [1,3]. Most
cases of early PTLD are due to EBV while most cases of late
PTLD are EBV negative. Apart from affecting the allograft,
extranodal PTLD has a predilection for the gastrointestinal
tract [4]. PTLD is often a silent disorder however patients may
develop non-specific symptoms such as fever, weight loss and
fatigue secondary to the viral infection or lymphadenopathy.
Other symptomology occurs secondary to mass effect of
surrounding organs or structures [5].

While rare, PTLD can present with perforation of
hollow viscus. There is a lack of guidelines for the surgical
management of abdominal catastrophes related to PTLD.
Identification of and resection of the perforation should be
performed with either diversion of fecal stream or primary
anastomosis depending on the clinical situation.
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Case Presentation
This is a 61-year Caucasian female who presented to the
emergency department with a fifteen hour history of acute
onset abdominal pain. The pain progressed from sharp,
constant pain in her left abdomen to diffuse abdominal
pain. The patient denied other symptoms including nausea,
emesis, fevers, and chills. Past medical history was positive
for squamous cell skin cancer, arthritis, hypertension,
hypothyroidism, and autoimmune hepatitis. Past surgical
history consisted of liver transplant in 1992 secondary
to autoimmune hepatitis, appendectomy, tonsillectomy,
thyroidectomy, breast lumpectomy, and excision of skin cancer.
She has no significant family history. Her immunosuppressive
regimen consisted of 175 mg Azathioprine every night, 3 mg
Tacrolimus daily, and 13 mg of Prednisone daily.
Dedicated physical examination was performed revealing
tachycardia with otherwise stable vitals. The patient's
abdomen was firm with diffuse tenderness to palpation with
increased sensitivity in the left, lower quadrant. There was

Image 1

a palpable mass in the left lower quadrant. Four quadrant
percussion and rebound tenderness were present with
involuntary guarding. Laboratory analysis was significant for
a leukocytosis of 12.5 bil/L, neutrophilic left shift of 11.1 bil/L,
and lactic acidosis of 2.5 mmol/L. The patient underwent
computed tomography of the abdomen and pelvis with IV
contrast as pictured in the below images.

Preoperative Imaging
A CT of the abdomen and pelvis with intravenous
contrast was performed that revealed jejunal bowel wall
thickening indicated by the measurement caliper and arrow
on axial Figure 1. The extent of wall thickening is also well
demonstrated on coronal Figure 2 where nearly the entire
segment of affected jejunum can be seen in the left abdomen,
along with adjacent vascular engorgement. This image also
demonstrates the presence of trace free fluid in the left lower
quadrant and perihepatic space. There was also significant
fat stranding surrounding the loop of jejunum, indicative
of acute inflammation. Several images also demonstrate

Image 2

Image 4

Image 3

Image 5

Figure 1-5: A CT of the abdomen and pelvis with intravenous contrast was performed. Note the jejunal bowel wall thickening indicated
by the measurement caliper and arrow on axial image 1. The extent of wall thickening is also well demonstrated on coronal image 4
where nearly the entire segment of affected jejunum can be seen in the left abdomen, along with adjacent vascular engorgement.
Note the presence of trace free fluid in the left lower quadrant and perihepatic space on the same image. There was also significant
fat stranding surrounding the loop of jejunum, indicative of acute inflammation. Also note the surgical suture material in the anterior
abdominal wall from the patient’s prior liver transplant (best seen on image 2). Several images also demonstrate multiple foci of air
throughout the mesenteric fat, consistent with pneumoperitoneum from jejunal perforation (indicated by the arrows on coronal view,
image 3). On axial image 5, a segment of thickened small bowel is demonstrated. The arrow indicates a focal air-containing defect in
the bowel wall, suggesting a possible perforation site.
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multiple foci of air throughout the mesenteric fat, consistent
with pneumoperitoneum from jejunal perforation, as seen on
Figure 3, Figure 4. On axial Figure 5, a segment of thickened
small bowel is again demonstrated. The arrow indicates a
focal air-containing defect in the bowel wall, suggesting a
possible perforation site.

diffuse large B cell lymphoma being the most common type.
[1, 7,8] The incidence of PTLD varies depending on the type
of transplant (with highest reported incidence in small bowel
and multi-organ transplants) and is estimated to be 0.8-20%.
A higher incidence has been attributed to the higher levels of
immunosuppression required in these types of transplants. [2,9]

Pre-operative discussion was held between the surgical
team and the patient with shared decision making. Given
the imaging studies in the setting of an acute abdomen, the
patient was taken emergently to the operating room for
exploratory laparotomy. Extensive succus was encountered
upon entry into the abdominal cavity. The bowel was
examined proximally too distally in the standard fashion until
a perforation was encountered on the antimesenteric side of
a loop of bowel in the distal jejunum. Pathologically enlarged
lymph nodes were confirmed near the site of perforation.
Small bowel resection was performed with five centimeter
margins proximally and distally. An extensive wash-out was
performed with great yield and limited post-procedural
contamination. A side-to-side stapled anastomosis was
created without a diverting ostomy. The rest of the small
intestine as well as the large intestine were inspected with
no further areas of perforation noted. The patient was safely
extubated and transferred to recovery in stable condition.

There is a known association between EBV infection
and PTLD with an estimated 70-80% of cases being EpstinBarr positive. While immunocompetent hosts infected with
EBV can clear the primary infection, the virus may persist in
B-lymphocytes in a latent state. There are four different types
of latency associated with EBV which are differentiated by
the EBV antigen expression pattern in infected B-cells. In EBV
positive PTLD patients, the most common latency pattern is
Type III [3]. Patients are at highest risk of developing PTLD
one year after transplantation when immunosuppression is
at its highest and these cases are most commonly driven by
EBV. In EBV negative PTLD the pathogenesis is not as well
defined. EBV negative PTLD occurs more commonly in older
transplant patients, is a monomorphic type, and often has
high risk features [10]. In this case report, final pathology
demonstrated monoclonal, diffuse Large B-cell lymphoma
with high proliferation rate, double expressor subtype (coexpression of BCL and c-myc). Analysis demonstrated rare
Epstein Barr encoding region (EBER) presence in neoplastic
B cells with the majority of neoplastic cells negative for EBER.
While it is unclear the significance of the rare EBER presence
in neoplastic B cells, most patients with EBV positive PTLD
present within one year of transplant. With the majority of
neoplastic cells negative for EBER we believe pathogenesis of
this patient’s PTLD is likely EBV negative which is consistent
with the monoclonal lineage and higher grade of malignancy.

The patient had an uneventful postoperative recovery. Her
diet was advanced and pain was well controlled. Preliminary
pathology results came back with concern for lymphoma.
Hematology and oncology was consulted and diagnosed the
patient with post-transplant lymphoproliferative disorder.
The patient was discharged home in stable condition. Several
days later the final pathology report revealed monomorphic
post-transplant lymphoproliferative disorder, diffuse large
B-Cell lymphoma with high proliferative rate, double express
or subtype. The patient followed up with the department of
hematology and oncology after discharge and was prescribed
DA-REPOCH regimen. In addition, the patient followed
up with her transplant hepatology team who decreased
the patient’s immunosuppression regimen. The patient
has had several hospital admissions since her surgery for
inpatient chemotherapy sessions which were complicated
by cytomegalovirus (CMV) infection, cellulitis and hospital
acquired pneumonia and Pneumocystis Carinii Pneumonia
(PCP). She is currently doing well and has completed
chemotherapy.

Discussion
Post-transplant lymphoproliferative diseases are
known complications following solid organ transplant and
hematopoietic stem cell transplant. This pathology was
first described in 1968 by Doak, et al. who highlighted two
cases following renal transplantation [6]. It was formally
described and categorized as a distinct clinical entity in the
2008 WHO classification of lymphomas. In 2016 the World
Health Organization updated their classifications of PTLD
with 6 categories: Plasmalytic hyperplasia PTLD, infectious
mononucleosis PTLD, florid follicular hyperplasia PTLD,
polymorphic PTLD, monomorphic PTLD, and classical Hodgkin
lymphoma. The majority of cases are of B cell origin with
Rosado M et al. J Transplant Surg 2021, 4(1):75-79

Histological Evaluation of Pathology
Figure 6, Figure 7, Figure 8 demonstrate preserved small
intestine with ulcer bed and abnormal expansion of the
lamina propria by atypical large cells. Figure 6 is a high power
replicated view with stains indicating CD20 positive cells, a
B-cell lineage marker. Figure 7 demonstrates the majority of
cells are expressing C-myc protein, consistent with a c-myc
translocation that is seen in Burkitt lymphoma and so called
“double hit” lymphomas. In the clinical setting of transplant,
the diagnosis is that of a post transplant lymphoproliferative
disorder, likely Burkitt subtype. Figure 8 is a high power view
with staining for Ki-67, indicating a high proliferation rate.
The high Ki-67 stains and CD20 staining reveals that this is an
aggressive B cell neoplasm.
Unfortunately, the symptoms of PTLD are quite vague with
many patients being asymptomatic. Patients may present with
viral symptoms, unexplained fever, or lymphadenopathy. They
may also present with signs related to allograft dysfunction,
with the allograft and the gastrointestinal tract being some
of the most common extranodal sites [7]. Gastrointestinal
symptoms can vary widely from vague abdominal pain,
diarrhea, and lack of appetite to gastrointestinal bleeding,
obstruction, and perforation [11-15]. In a retrospective study
published by Cruz, et al. at the University of Pittsburgh, a total
of 5,677 adult patients were studied with liver transplants
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Figure 6-8: Histological evaluation of pathology: Images 6-8 demonstrate preserved small intestine with ulcer bed and abnormal
expansion of the lamina propria by atypical large cells. Image 6 is a high power replicated view with stains indicating CD20 positive cells,
a B-cell lineage marker. Image 7 demonstrates the majority of cells are expressing C-myc protein, consistent with a c-myc translocation
that is seen in Burkitt lymphoma and so called “double hit” lymphomas. In the clinical setting of transplant, the diagnosis is that of a
post transplant lymphoproliferative disorder, likely Burkitt subtype. Image 8 is a high power view with staining for Ki-67, indicating a
high proliferation rate. The high Ki-67 staining and CD20 staining reveals that this is an aggressive B cell neoplasm.

performed from January 1983-December 2019. They
identified thirty six patients who developed gastrointestinal
PTLD, sixteen of which required emergency surgery. Of those
sixteen patients, seven required surgery due to obstruction,
six due to perforation and three due to gastrointestinal
bleeding. Of the six perforations, two occurred following the
initiation of chemotherapy [15].
Gastrointestinal perforation is an incredibly rare
presentation of PTLD with only limited case reports and case
series. In a literature review performed using Google Scholar and
PubMed with keywords “post-transplant lymphoproliferative
disorder” and “perforation”, approximately seventeen cases
of spontaneous gastrointestinal perforation as the initial
presentation of PTLD have been reported [13,15-18]. To the
best of our knowledge this case is the first reported case
of PTLD diagnosed in a patient so late after transplant with
the patient’s perforation occurring 27 years following liver
transplant.
Radiology plays an important role in the early diagnosis
of PTLD lesions, in guiding biopsy, and in surveillance
of treatment response. Contrast-enhanced computed
tomography (CT) is the most widely used modality due to its
ease of use and wide availability. Abdominal disease is seen in
50%-75% of patients with PTLD following renal, liver, or heart
transplant and the abdominal cavity is the most frequently
involved compartment in PTLD [19]. Bowel wall thickening
is a nonspecific finding that, in the emergent setting, can
be indicative of underlying inflammation. Wall thickening
and dilation are the most common imaging findings in small
bowel involvement of PTLD, followed in order of decreasing
frequency by eccentric mass, luminal ulceration, and shortsegment intussusception [19]. Extra nodal involvement is
more common than nodal involvement in intra-abdominal
disease [20], and the gastrointestinal tract and liver are the
most commonly involved sites, although the prevalence
of organ involvement varies with the type of transplant
[19]. The imaging features of gastrointestinal involvement
by PTLD are similar to those of non-Hodgkin lymphoma in
Rosado M et al. J Transplant Surg 2021, 4(1):75-79

immunocompetent patients, although ulceration is more
common [21]. The distal small bowel is the most common site
of involvement of hollow viscera, followed by the proximal
large bowel, stomach, duodenum, and esophagus. The distal
jejunum and ileum are the most common sites of small bowel
disease [19].
The current standard for treatment of solid organ
transplant PTLD, regardless of EBV status, is reduction of
immunosuppression (RIS) with the addition of rituximab and
chemotherapy [22]. Rituximab is a monoclonal anti-CD20
antibody which when combined with RIS has demonstrated
improved overall response rates and complete response
rates. While rituximab certainly changed the management of
lymphoma and PTLD, it has a rare side effect of gastrointestinal
perforation. A warning was issued by the manufacturer in
2006 warning of the very rare occurrence of perforation with
their database recording 37 gastrointestinal perforations in a
total of 730,000 patients. In this case report, the patient was
treated with reduction in immunosuppression, chemotherapy,
and rituximab (DA-REPOCH). Fortunately, she was able to
complete treatment without complication of perforation.
In one case report a patient presented with spontaneous
intestinal perforation several months after bone marrow
transplant successfully managed with emergent laparotomy.
Postoperatively, they were treated with rituximab and
developed a second intestinal perforation which was fatal
[16]. While the complication of intestinal perforation with
rituximab is exceedingly rare, it is important for the clinician
managing the PTLD patients to be aware of this complication,
especially if the presentation is with intestinal perforation.
Post-transplant lymphoproliferative disorder is a rare
hematologic malignancy occurring after hematopoietic
stem cell or solid organ transplant. It is very rare for PTLD to
present with intestinal perforation. This case report describes
the successful management of an abdominal catastrophe
in a patient 27 years following liver transplantation on
immunosuppressive therapy. The patient was successfully
treated with laparotomy, small bowel resection and primary
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stapled side to side anastomosis. With a multi-modality
approach to her surgical aftercare, the patient's pathology
was properly managed and she continues to progress
in her health. We describe one of few reported cases of
gastrointestinal perforation as the initial presentation of PTLD
after solid organ transplantation. To the authors' knowledge,
we also present a patient with the longest latency from solid
organ transplantation to diagnosis of PTLD following intestinal
perforation that has been reported in the literature.
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